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Abstract. The extent of gene polymorphisms associated with resistance to chloroquine and sulfadoxine-
pyrimethamine was examined in field isolates of Plasmodium falciparum from Indonesia. Eight malaria-endemic areas,
representing a broad region of the western and eastern Indonesian Archipelago were surveyed. Blood from 20−50
patients was collected at each site, DNA was isolated, and the sequences of four different genes (dihydrofolate reductase
[dhfr], dihydropteroate synthase [dhps], P. falciparum multidrug resistance 1 [pfmdr1], and P. falciparum chloroquine
resistance transporter [pfcrt]) were analyzed using polymerase chain reaction and restriction fragment length polymor-
phisms to detect polymorphisms previously shown to be associated with resistance. This analysis identified polymor-
phisms in dhfr at 108-Asn/Thr, 16-Val, and 59-Arg. Polymorphisms in dhps were found less frequently, either 437-Gly
alone or paired with 540-Glu. The pfcrt 76-Thr polymorphism was fixed in all parasite populations and pfmdr1 86-Tyr
polymorphisms in all populations except in the most eastern regions. The pfmdr1 1042-Asp polymorphism occurred less
frequently. These findings indicate that polymorphisms in genes associated with drug resistance in P. falciparum are
found across a broad region of Indonesia.
INTRODUCTION
Since the first reports of chloroquine resistance in East
Kalimantan and Indonesian Papua in 1975,1 chloroquine re-
sistance has been observed in all areas of the archipelago
where in vivo/in vitro studies have been conducted.2–12 As a
consequence of this widespread resistance, a combination of
the antifolates sulfadoxine and pyrimethamine was intro-
duced as a second-line treatment of simple malaria. The syn-
ergistic combination of the two, which inhibit dihy-
dropteroate synthase and dihydrofolate reductase, respec-
tively, in the folate biosynthetic pathway, was believed to
enhance their antimalarial potency and reduce the risk of
drug resistance.13,14 However, resistance to this drug combi-
nation had already been observed in Indonesia,1 and has now
spread across the archipelago.3,8,10,15–17 The resistance of ma-
laria parasites to Fansidar (Fansidar Hoffmann La Roche,
Basel, Switzerland), the most commonly used combination
of sulfadoxine-pyrimethamine, is now widespread in south-
east Asia.18–22 Despite the spread of resistance to these
antimalarials in Indonesia, chloroquine and sulfadoxine-
pyrimethamine are still used as first-line and second-line an-
timalarial drugs, respectively.
Molecular studies over the last few decades have identified
several mutations associated with chloroquine and sulfadox-
ine-pyrimethamine resistance in a number of Plasmodium fal-
ciparum genes. Polymorphisms in the P. falciparum chloro-
quine resistance transporter (pfcrt) gene, located on chromo-
some 7, were proposed to be important in chloroquine
resistance and transfection experiments have shown that the
polymorphism 76-Ser to Thr is tightly linked to the resistance
phenotype.23,24 Additionally, polymorphisms in the P. falci-
parum multidrug resistance 1 (pfmdr1) gene have been shown
by transfection to modulate higher levels of chloroquine re-
sistance and also to affect mefloquine, halofantrine, and qui-
nine resistance.25,26
The molecular basis of resistance to pyrimethamine and
sulfadoxine has been more clearly defined. Polymorphisms in
the dihydrofolate reductase (dfhr) gene that alter 108-Ser to
Asn/Thr in the enzyme have been shown to confer resistance
to pyrimethamine.27 Additional polymorphisms at amino acid
positions 50, 51, 59, and 164 combined with 108-Asn confer
increasing levels of pyrimethamine resistance.28 The combi-
nation of 16-Ala to 16-Val and 108-Ser to 108-Thr confers
resistance to cycloguanil but retains sensitivity to pyrimeth-
amine.29,30 Similarly, polymorphisms in the dihydropteroate
synthase (dhps) gene confer resistance to sulfadoxine.31 The
polymorphism 437-Gly in dhps appears to be the first to be
selected by drug pressure and it encodes lower level resis-
tance to sulfadoxine. Subsequent polymorphisms at positions
436, 540, 581, and 613 confer increasing levels of resistance to
this drug.32
Epidemiologic studies have been conducted in all malaria
endemic areas of the world looking at polymorphisms in the
aforementioned genes and their relationship with treatment
failure or resistant P. falciparum.7,17,33–37 The aim of the
present study was to complement existing knowledge of in
vivo and in vitro antimalarial drug responses in Indonesia by
determining the extent of associated gene polymorphisms in
P. falciparum isolates from different malaria-endemic areas.
The information obtained will contribute to the development
of strategies for therapeutic intervention of malaria in Indo-
nesia.
MATERIALS AND METHODS
Study sites. Eight malaria-endemic areas that represent the
entire Indonesia archipelago (Figure 1) were selected for
sample collection. Four areas (Nias, Lampung, Kokap, and
Kutai) are located in western Indonesia and four (Minahasa
Mamuju, Flores, and Armopa) in eastern Indonesia. In each
area, 20−50 blood samples infected with P. falciparum isolates
were collected from people either with malaria fever or ap-
parently healthy individuals. In these selected areas, chloro-
quine is used as the first-line antimalarial drug and sulfadox-
ine-pyrimethamine is used as the second-line antimalarial
drug. Primaquine, in combination with either of the above, is
used for radical cure. Parenteral quinine is exclusively used as
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a life-saving antimalarial drug in severe and complicated ma-
laria. This study was carried out with the approval of the
Ethics Committees for Protection of Human Subjects at the
Eijkman Institute for Molecular Biology (Jakarta, Indonesia)
and The Walter and Eliza Hall Institute (Melbourne, Victo-
ria, Australia).
Sample collection. A malariometric survey was conducted
in a selected village in each area, and blood samples were
collected via one or more of the following methods: in anti-
coagulant tubes, smears on a glass slide, or as a blot on filter
paper (3MM; Whatman, Hillsboro, OR). Plasmodium
falciparum−infected samples, as revealed by microscopic ex-
amination of a slide smear, were used for DNA isolation.
Extraction of DNA. Parasite DNA was extracted from the
blood samples using Chelex-100 ion exchanger (Bio-Rad
Laboratories, Hercules, CA) essentially according to the pro-
cedure described previously.38 The DNA was either used im-
mediately for a polymerase chain reaction (PCR) or stored at
−20°C for later analysis.
Polymerase chain reaction amplification. Nested PCRs
were performed for four genes: dhfr, dhps, pfmdr1, and pfcrt.
All reactions were carried out in 50-L reaction mixtures
containing 50 mM KCl, 10 mM Tris-HCl, pH 8.3, 1.5 mM
MgCl2, 200 mM dNTP, 1 unit of Taq polymerase (Sigma, St.
Louis, MO), and a pair of primers (20 pM each). One to five
microliters of DNA was used as template in the first reaction
and 1−2 L of the first-round PCR product was used as tem-
plate for the secondary PCR. Positive (D10 DNA) and nega-
tive (water) controls were used in all PCRs. The PCR primers
and conditions were as previously described for dhfr, dhps,
and pfmdr1,39,40 and pfcrt.23,24 Secondary PCR products were
resolved by electrophoresis on 1–2% agarose gels and visu-
alized by staining with ethidium bromide.
Restriction fragment length polymorphism (RFLP). Re-
striction enzyme digestion of either the native or introduced
sites of the PCR products was performed to determine the
presence of polymorphisms in dhfr, dhps, pfmdr1,39–42 and
pfcrt.23−25 A number of restriction enzymes were used for
RFLP of PCR products. For dhfr, the PCR products were
digested with Nla III, Tai I, Tsp 509I, Xmn I, and Dra I to
determine the polymorphisms at codons 16, 50, 51, 59, and
164, respectively. Three enzymes, Alu I, Bsr I, and Scr FI,
were used to identify codon 108. For dhps, the PCR products
were digested with Msp A1I, Ava II, and Fok I to determine
the polymorphisms at codon 436, 437, and 540, respectively.
In addition, restriction enzymes Bst UI and Bsl I were used to
identify polymorphisms at codon 581, while Mwo I, Bsa WI,
and Age I were used for codon 613. Similarly, pfmdr1 PCR
products were digested with Afl III, Dde I, Ase I, and Eco RV
to determine the presence of polymorphisms at codons 86,
1034, 1042, and 1246, respectively. For pfcrt PCR products,
the polymorphism at codon 76 was examined by digestion
with Apo I. To determine complete digestion, introduced or
natural restriction sites in the DNA fragment served as con-
trols. If no such restriction sites were present, a known PCR
product carrying the required restriction sites was used. As an
additional control in every RFLP experiment, 0.5 g of pu-
rified lambda DNA (Promega, Madison, WI) was digested to
monitor the enzyme activity. Digested products were sub-
jected to electrophoresis on 1.5−3% agarose gels (Progen,
Australia) or 1.5−3% ultrapure agarose gels (Progen, Austra-
lia) when a higher resolution was required. Loss of restriction
FIGURE 1. Map of the Indonesian archipelago and the sampling sites (boxes) of the isolates of Plasmodium falciparum.
EPIDEMIOLOGY OF P. FALCIPARUM DRUG RESISTANCE IN INDONESIA 175
sites in the DNA fragment for the enzymes Nla III, Tsp 509I,
Dde I, and Ase I or a gain in the restriction sites for Tai I,
Xmn I, Bsr I, Scr FI, Dra I, Msp A1I, Ava II, Fok I, Bsl I, Bsa
WI, Age I, Afl III, and Eco RV indicated that the DNA
fragments carried polymorphisms. If there was an indication
of incomplete digestion in a sample, the digestion were re-
peated with overnight incubation to confidently accept the
presence of a mixed allelic population. These cases were con-
sidered to be mixed infections.
RESULTS
A total of 213 P. falciparum isolates from eight malaria-
endemic areas in Indonesia were analyzed. Some samples,
particularly those collected on filter paper, failed to amplify
using certain primers; thus, the gene polymorphism informa-
tion obtained was incomplete. Based on gene analysis, there
were 83 samples (38.9%) that gave PCR results indicating
mixed isolates, either as polymorphic and wild-type or two
polymorphic types.
Genotypic profiles of P. falciparum isolates from west-
ern Indonesia. Polymorphisms in the pfmdr1 and pfcrt
genes. Analysis of 117 isolates from Nias Island, Hanura,
Kokap, and Kutai showed that polymorphisms in the pfmdr1
and pfcrt genes have spread to all sample collection sites
(Table 1). Except in one sample from Nias Island that failed
to be amplified, all (116 of 116) isolates carried the 86Y poly-
morphism in pfmdr1. No polymorphisms at codons 1034,
1042, and 1246 of the pfmdr1 gene were observed in any of
the isolates examined. Likewise, for pfcrt, 100% (85 of 85) of
the amplified samples carried the 76T polymorphism.
Polymorphisms in the dhfr and dhps genes. Amplification
of dhfr 108 was successful with 92 isolates (Table 1). Of these,
54% (50 of 92) had either a single polymorphism, 108N, or the
mixed S108N and 19% (17 of 92) had either 108T or 108T
mixed with wild-type. An additional 13% (12 of 92) carried
the mixture 108N/T. Except for one isolate from Kutai, the
threonine polymorphism was found only at Hanura and
Kokap. Only 14% (13 of 92) of the successfully amplified
isolates for dhfr 108 carried a single wild-type haplotype.
Analysis of codon 59 was successful in 90 of the 92 amplified
isolates. This identified 54% (49 of 90) as being wild-type C59
while the other 46% (41 of 90) were either 59R or 59R mixed
with wild-type. The C59R polymorphism was in all cases as-
sociated with one or other of the 108 resistance polymor-
phisms. At Kutai, the 59R polymorphism was not observed.
At dhfr codon 16, the wild-type A16 was observed in 62% (16
of 26) of isolates from Kokap and the single polymorphism
16V or the mixed A16V was observed in 38% (10 of 26) of the
isolates. This polymorphism was only observed in association
with 108T as either a single or mixed population. Codon 16
was only observed as wild-type at all other locations in the
western part of Indonesia. No polymorphisms were observed
at codons 50, 51, or 164 in any of the samples examined.
Polymorphisms in the dhps gene were the least common
among the four genes tested in this study (Table 1). The most
common polymorphism was 437G, which was observed in
Hanura, Kokap, and Kutai; however, only in 14% (16 of 117)
of all isolates. The double polymorphism of codons 437G and
540E was observed in one sample from Kokap, in association
with dhfr 59R and 108N/T. No polymorphisms were observed
at codons 436, 581, or 613 in any of the samples examined in
this study.
Genotypic profiles of P. falciparum isolates from eastern
Indonesia. Analysis of pfmdr1 and pfcrt genes. Analysis of 71
isolates that successfully amplified pfcrt codon 76 identified
91% (64 of 70) with the polymorphism 76T and one isolate
from each of Flores and Armopa were mixed K76T (Table 2).
For pfmdr1, the results were more complex, with the 86Y
polymorphism ranging from 95% (19 of 20) at Minahasa to
16% (3 of 19) at Flores. However, the 84% (16 of 19) of
isolates from Flores that carried the wild-type N86 were ob-
served to have the polymorphism 1042D. At Armopa, 27% (4
of 15) of the isolates carried the 86Y polymorphism and all
isolates were wild-type at codon 1042. The 1042D polymor-
phism was also observed in 15% (3 of 20) of isolates from
Minahasa.
Point mutations in the dhfr and dhps genes. Eighty-three
samples were successfully amplified at dhfr 108, of which only
10% (8 of 83) were wild-type S108. The rest were either 108T
(34%, 28 of 83), S108T (20%, 17 of 83), 108N (19%, 16 of 83),
S108N (12%, 10 of 83) or 108N/T (5%, 4 of 83). Eighty iso-
lates were successfully analyzed for polymorphisms at codon
59. A total of 68% (54 of 80) were wild-type C59 and 32% (26
of 80) were either 59R or the mixed 59R with wild-type
(Table 2). At codon 16, the polymorphism 16V was observed
twice at Mamuju, once in association with 108T and once with
59R and 108T. In Flores, 16V was observed once in associa-
tion with 108T and once as the mixed A16V in association
with S108T. No polymorphisms were observed at codons 50,
51, and 164 in any of the samples examined.
Analysis of dhps showed that 13% (13 of 96) of the isolates
were either 437G or A437G. One isolate from Minahasa car-
ried the 540E polymorphism associated with 437G and dhfr
S108T. A single isolate from Armopa carried dhps K540G in
association with A437G and dhfr C59 and S108. No mutation
was observed at codons 436, 581, and 613 in any of the
samples examined in this study.
DISCUSSION
As might have been expected from the previous extensive
studies on in vivo and in vitro antimalarial drug responses in
Indonesia, the isolates of P. falciparum examined in this study
were found to carry multiple genetic polymorphisms associ-
ated with resistance to chloroquine and sulfadoxine-
pyrimethamine.
Although the molecular basis for the P. falciparum resis-
tance to quinoline antimalarials is still being investigated, evi-
dence indicates that resistance is multigenic. Initially, the role
of mutations in pfmdr1 in the modulation of chloroquine re-
sistance was shown.27 Allelic exchange experiments have in-
dicated that the 1246 Tyr polymorphism in pfmdr1 increases
the chloroquine 50% inhibitory concentration (IC50) and,
both alone and in combination with the polymorphisms 1034
Cys and 1042 Asp, also modulates sensitivity to other anti-
malarials drugs.28 However, a detailed linkage analysis and
chromosomal mapping of progeny identified a second gene
involved in chloroquine resistance, pfcrt, in which mutation at
codon 76, K76T is strongly associated with the chloroquine
resistance phenotypes in field and clinical studies.23–25 Fur-
thermore, conclusive evidence that various mutant pfcrt hap-
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lotypes confer chloroquine resistance with characteristic ve-
rapamil reversibility and reduced chloroquine accumulation
was demonstrated.26 Nevertheless, the role of other modify-
ing factor such as pfmdr1 in this regard could not be excluded.
Previous field-based studies in Indonesia have associated
the 86Y allele of the pfmdr1 gene to chloroquine resistance,
both in vivo and in vitro.8,41 Other studies in Indonesia have
reported that the 76T polymorphism of pfcrt is also associated
with chloroquine resistance in vivo and in vitro, and the allele
has the potential to be used as a predictor for chloroquine
therapeutic treatment failure.7,42 Our present results show
that the isolates of P. falciparum from Indonesia carry poly-
morphisms in both the pfcrt and pfmdr1 genes. In western
Indonesia, all asymptomatic and mildly symptomatic malaria
patients were carrying parasites with both pfcrt 76T and
pfmdr1 86Y polymorphisms. The situation in eastern Indone-
sia was more complex (Figure 2). Northern Sulawesi had a
resistant profile at these two codons, whereas southern Su-
lawesi had a lower frequency of pfmdr1 86Y polymorphism
than may have been expected, but pfcrt was fixed in the para-
site population. In Flores, all isolates carried 76T and all iso-
lates carried a polymorphism in pfmdr1. However, most of
TABLE 1
Genotypic pattern of Plasmodium falciparum isolates from western Indonesia*
Locations
No. of
genotypes
DHFR DHPS Pfmdr1
PfCRT
76T
No. of
isolates16V 59R 108N/T 437G 540E 86Y 1042D
Nias, North Sumatra 1. A C S A K Y N T 1
2. A C N A K Y N T 2
3. A R N A K Y N T 9
4. A C/R S/N A K Y N T 3
5. A – N A K Y N T 1
6. A – S/N A K Y N T 1
7. – – – A K Y N T 2
8. – – – A K – – T 1
Hanura, Lampung 1. A R N A K Y N T 3
2. A R S/N A K Y N T 2
3. A R N A/G K Y N T 2
4. A C S/N A K Y N T 4
5. A R N A/G K Y N T 3
6. A C S/N A/G K Y N T 1
7. A R N/T A K Y N T 1
8. A C/R N/T A K Y N T 2
9. A C/R N/T G K Y N T 2
10. A C/R N/T A/G K Y N T 3
11. A C/R S/N A/G K Y N T 1
12. A C S A K Y N – 3
13. A C T A K Y N – 2
14. A R N A K Y N – 1
15. – – – A K Y N T 1
16. – – – A K Y N – 10
Kokap, Central Java 1. A C S A K Y N T 2
2. A R N A K Y N T 3
3. A C T A K Y N T 2
4. V C T A K Y N T 2
5. A C/R N A K Y N T 1
6. V C N/T A K Y N T 1
7. A R N/T A K Y N T 1
8. A R N/T G E Y N T 1
9. A C/R S/N A K Y N T 1
10. A/V C S/T A K Y N T 1
11. A/V C/R N/T A K Y N T 1
12. V C T A K Y N T 3
13. A R N A K Y N T 1
14. A C S/T A K Y N – 1
15. A/V C S/T A K Y N – 1
16. A C N A K Y N – 1
17. A C T A K Y N – 2
18. A/V C T A K Y N – 1
19. – C T A K Y N – 1
20. – – – A K Y N T 1
Kutai, East Kalimantan 1. A C S A K Y N T 5
2. A C N A K Y N T 5
3. A C S/T A K Y N T 1
4. A C S/N A K Y N T 3
5. A C S A/G K Y N T 1
6. A C N A/G K Y N T 2
7. A C S A K Y N – 1
8. – – – A K Y N T 2
9. – – – A K Y N – 8
* DHFR  dihydrofolate reductase; DHPS  dihydropteroate synthase; Pfmdr1 = P. falciparum multidrug resistance 1; PfCRT = P. falciparum chloroquine resistance transporter.
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TABLE 2
Genotypic pattern of Plasmodium falciparum isolates from eastern Indonesia*
Locations
No. of
genotypes
DHFR DHPS Pfmdr1
PfCRT
76T
No. of
isolates16V 59R 108N/T 437G 540E 86Y 1042D
Minahasa, North Sulawesi 1. A C T A K N/Y N K 1
2. A C N A/G K Y N T 1
3. A C S/N A K Y N T 2
4. A C S/N G K Y N T 1
5. A C/R N/T A K Y N T 1
6. A C S/N A K N/Y N – 1
7. A C S/N G K Y N – 1
8. A C S/T A K Y D – 1
9. A C S/T G K Y D – 1
10. A C S/T G E N D – 1
11. A C N/T A K Y – T 1
12. A C N A K – N T 1
13. A C S/T A K – – T 2
14. A C N/T A K – – T 1
15. A C/R N/T A K – – T 1
16. A C S/T A K – N – 2
17. A C S/T A K – – – 3
18. – – – A K Y N T 3
19. – – – A K Y N – 1
20. – – – A/G K Y N – 1
21. – – – A K – N T 1
22. – – – A K Y – T 2
23. – – – A/G K – N – 1
24. – – – A K – N – 2
25. – – – A/G K Y – – 1
Mamuju, South Sulawesi 1. A C T A K Y N T 2
2. V R T A K Y N T 1
3. A C N A K N N T 4
4. A C N A K Y N T 1
5. A C S/N G K N N T 1
6. A C T A K Y N – 5
7. A C/R T A K Y N – 1
8. A C T A K – – T 2
9. A C/R T A K – – T 1
10. V C T A K – – T 1
11. A R T A K – – T 2
12. A C T A K – – – 1
13. – – – A K N N T 1
Flores, East Nusa Tenggara 1. A R T A K N D T 2
2. A C S A K Y N T 1
3. V C T A K N D T 1
4. A C T A K N D T 5
5. A C T A K Y N T 1
6. A C S A K N D T 1
7. A C S/T A K N D T 1
8. A R S/T A K N D T 3
9. A C T A K N D K/T 1
10. A C/R S/T A K N/Y N/D T 1
11. A – S/T A K N D T 1
12. A/V – S/T A K N D T 1
13. A – T A K – – T 1
Armopa, West Papua 1. A C S A/G K/E N N T 1
2. A C/R S/N A K N N T 3
3. A R N A K N N T 2
4. A R N G K N N T 1
5. A C S A K N N T 2
6. A R N A K N/Y N K/T 1
7. A C S A K N N K 1
8. A R N G K N/Y N T 1
9. A R N A K N N K 1
10. A C S A K Y N T 2
11. A R N A K – – – 2
12. A R N G K – – – 1
13. A C/R S/N A K – – – 1
* For definition of abbreviations, see Table 1.
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these were the 1042D polymorphism, without the expected
86Y polymorphism. Recent findings have shown that Papua
New Guinea and Papua Indonesia have a range of variants of
chloroquine-resistant P. falciparum parasites at pfcrt codons
72–76.42,43 These variants encompass African, southeast
Asian, and South American haplotypes. While work on this
area of parasite evolution is still in its early stages, future
studies may conceivably show an association between re-
gional pfmdr1 and pfcrt haplotypes. Given that the pfmdr1
1042D polymorphism is far more common in South America,
further work on this aspect could show interesting results. In
isolated Papua, pfcrt 76T appears to be fixed in the parasite
population; however, there is only a low rate of polymor-
phism in pfmdr1. In our previous study in Armopa, Papua
Province involving Javanese migrants who have easier access
to the Health center than the indigenous Papuans, a high
prevalence of 86Y polymorphism was found in the P. falci-
parum isolates examined.8 A closer examination of the social
and chemotherapeutic history in this particular area may shed
more light on this apparent contradiction. It is of interest to
note the occurrence of two isolates in Minahasa carrying both
86Y and 1042D polymorphisms of pfmdr1. A recent study
also reported this allele from Purworejo district in the island
of Java.12 This finding may be associated with the civil strife
in the eastern parts of Indonesia that has resulted in migration
to Java.
Given the spread of chloroquine treatment failure to many
parts of Indonesia over the last two decades,5,7,8,9,11,17,44 it
was not surprising to find that P. falciparum isolates in Indo-
nesia carry the polymorphisms in pfmdr1 and pfcrt that have
been associated with resistance to this drug.
The P. falciparum isolates examined carried polymor-
phisms in dhfr as either 108N or 108T as well as the 59R and
16V polymorphisms. There are two antifolate drugs that have
been used in Indonesia, pyrimethamine and proguanil (cy-
cloguanil). Pyrimethamine has always been used in combina-
tion with sulfadoxine, whereas proguanil is available as a
single drug (Paludrine; AstraZeneca Pty., North Ryde, New
South Wales, Australia). Evidence to date indicates that the
molecular mechanism that underlies resistance to antifolate
antimalarials involves the S108N/T polymorphism of dhfr.
There is a differential target in the dhfr enzyme between
pyrimethamine and cycloguanil in which resistance to pyri-
methamine is mainly linked to the 108N polymorphism,
whereas cycloguanil resistance is linked to the 16V plus 108T
polymorphism. However, additional polymorphisms at 50A,
51I, 59R, and 164L will confer cross-resistance to both anti-
folate drugs.32 In our, study there was a relatively common
distribution of the 108T dhfr mutation, either as a single poly-
morphism or else paired with 16V among the field isolates of
P. falciparum from Indonesia. This single polymorphism has
been reported in laboratory clones45 and enzyme kinetic
analysis indicated that this mutant did not confer resistance to
cyloguanil. Conversely, the enzyme harboring mutant 16V
alone showed a high resistance to cycloguanil, but exhibited a
very low kinetic parameter, indicating that this mutation may
interfere with the fitness of the isolates and that the parasite
carrying this polymorphism may not survive in the natural
population of the parasite. The findings that no P. falciparum
isolates in Indonesia carried the 16V as a single mutation are
in line with this suggestion. However, as this previous work
reports, the poor dhfr activity of the A16V polymorphism was
restored in the presence of another mutation, 108T. There-
fore, it is strongly suspected that the 108T mutation in Indo-
nesia may serve as a precursor for the double mutant 16V plus
108T, which is highly resistant to cycloguanil.
The reported distribution of the single 108T polymorphism
among field isolates of P. falciparum has been very limited
and so far it has only been seen in isolates from Indonesia and
Papua New Guinea.46,47 In this regard, its relatively more
common distribution among the P. falciparum isolates from
the eastern part of Indonesia suggests that the isolates carry-
ing this polymorphism may share the same origin with the
isolate found in Papua New Guinea.
In this study, polymorphisms in the dhps gene were found
less frequently than polymorphisms in other genes. The high-
est rate of mutation (23%) was found in northern Sulawesi.
The most common mutation was 437G and in one sample
each from Kokap, northern Sulawesi, and Armopa; this was
paired with the 540E polymorphism. The role of dhps poly-
morphisms in the mechanism of resistance to sulfa drugs has
been well described.33,34 The presence of the 437G polymor-
phism confers resistance to sulfadoxine in P. falciparum, and
when coupled with the additional polymorphism at 540E the
level of resistance is increased.27 Our results indicate that the
P. falciparum isolates from Indonesia are still predominantly
wild-type dhps, a finding that reflects the results of recent
studies in the region in Papua New Guinea.48
There has been a disturbing report from Nias Island on the
high rate of P. falciparum treatment failure following sulfa-
doxine-pyrimethamine chemotherapy.17 In this study, no
dhps polymorphisms were found in samples from Nias Island,
and only very low rates of mutation at the other study sites.
Not withstanding the recent encouraging report from Malawi
on long-term sulfadoxine-pyrimethamine efficacy,49 this is a
worrying indicator for Indonesia. The combination of sulfa-
doxine-pyrimethamine is used as the second-line antimalarial
drug in Indonesia. While there is a lack of broad epidemio-
logic data available, what is published suggests that resistance
to this drug combination has spread to malaria-endemic areas
in Indonesia.8,15,17,44 Given this, serious consideration must
now be given to the use of artemisinin combination therapy,
FIGURE 2. Comparison of polymorphisms identified in west and
east Indonesia. The 1042D polymorphism of the Plasmodium falci-
parum multidrug resistance 1 (pfmdr1) gene was only found in east-
ern Indonesia. pfcrt  P. falciparum chloroquine resistance trans-
porter; dhfr dihydrofolate reductase; dhps dihydropteroate syn-
thase.
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which has already been shown to be effective against chloro-
quine-resistant strains of P. falciparum in Indonesia.6
In conclusion, molecular analysis of P. falciparum parasites
from eight malaria-endemic areas in Indonesia indicated the
widespread presence of isolates carry resistance polymor-
phisms to both the first-line antimalarial drug chloroquine
and to the second-line treatment sulfadoxine-pyrimethamine.
With widespread reports of treatment failure and the current
increase of malaria morbidity and mortality in Indonesia, se-
rious consideration should be given to the revision of the
guidelines for the chemotherapeutic treatment of malaria in
Indonesia.
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